Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 August 2022
Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2008
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 May 2025
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC